GP Bullhound advised Guidemark on its acquisition by Value Demonstration Group
“One need ahead” through a patient-first approach.
New York, 5 November 2021 - GP Bullhound acted as exclusive financial advisor to Guidemark Health, Inc. (“Guidemark”), a portfolio company of High Road Capital Partners, on its acquisition by Value Demonstration Group (“VDG”), a portfolio company of Arsenal Capital Partners.

Guidemark, headquartered in New Jersey, enables biopharmaceutical companies to stay “One Need Ahead” through patient-centric healthcare marketing, education and engagement. Its deep customer engagement and technology solutions, along with its unique mix of services (including marketing communications, training, and patient advocacy expertise) provide a differentiated service offering. Guidemark’s focus on oncology and rare diseases ensures that the Company is always on the frontlines of ground breaking research and development.

Guidemark is the third acquisition for VDG, following the acquisitions of BresMed Health Solutions and Cello Health plc. VDG is focused on creating unique solutions to develop and communicate evidence of value to optimize patient access to new therapies. The addition of Guidemark will further enhance VDG’s demonstrated ability to create deeper and more impactful engagement solutions targeted to the scientific, medical, and patient communities. These solutions connect human needs with innovative science and technology, from development through commercialization.

Michael Parisi, CEO of Guidemark commented: “We are thrilled with the recent sale of Guidemark to Arsenal Capital – our partners at GP Bullhound played a pivotal role throughout the entire process. Their knowledge of our space and the time they took to understand our needs and desires for a new partner resulted in an efficient and productive process – we couldn’t be happier with the outcome.”

Adam Birnbaum, Executive Director at GP Bullhound added: “It was a pleasure to advise Guidemark on this transformative transaction. The combination with VDG will help expand their medical affairs and commercial services. We are excited to be a part of their continued growth as they become a market-leader.”

The transaction marks the 29th transaction GP Bullhound has completed in the biopharma/health care marketing- digital services space. It represents further testament to the firm’s expertise in the healthcare marketing and communications sector, having previously advised on transactions for Giant, Glynn Devins, Snow, Heartbeat Digital, Eruptr and many others.

Enquiries
For enquiries, please contact:
Gregory Smith, Partner, gregory.smith@gpbullhound.com
Adam Birnbaum, Executive Director, adam.birnbaum@gpbullhound.com

About GP Bullhound
GP Bullhound is a leading technology advisory and investment firm, providing transaction advice and capital to the world’s best entrepreneurs and founders. Founded in 1999 in London and Menlo Park, the firm today has 10 offices spanning Europe, the US and Asia. For more information, please visit www.gpbullhound.com

Region
USA